GLP-1 medications like Ozempic can lead to weight loss, yes, but they can also impact your face, your personality, your sex ...

A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.

Cette décision a marqué le début d’une nouvelle ère pour la classe de médicaments à laquelle appartient l’Ozempic : les agonistes du peptide-1 de type glucagon (GLP-1). [Article issu de ...

Ozempic (semaglutide) is a brand-name drug prescribed to treat certain conditions, such as type 2 diabetes. Ozempic has interactions with some other drugs, such as insulin, and certain supplements ...

The move solidifies Ozempic as the most broadly indicated GLP-1 drug on the market. In the FLOW trial, the drug slashed the risk of severe kidney outcomes and cardiovascular-related deaths by 24% ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...

L'essai a révélé qu'Ozempic® 1 mg réduisait significativement le risque relatif d'aggravation de la maladie rénale, d'insuffisance rénale et de décès cardiovasculaire de 24 % par rapport à un placebo, ...

Novo's blockbuster diabetes drug Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same active ingredient as its popular obesity treatment Wegovy. The U.S. Food and ...

The trial revealed that Ozempic® 1 mg significantly lowered the relative risk of worsening kidney disease, kidney failure, and cardiovascular death by 24% compared to a placebo, in addition to ...